KRAS and non-small cell lung carcinoma: Recently, breakthroughs have been made in the development of KRAS‐targeted drugs, including AMG‐510, MRTX849 and other treatment such as immunotherapy, although the optimal treatment for KRAS‐mutated NSCLC patients has not yet been discovered.